INCB050465 1.0mg ( DrugBank: INCB050465 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
35天疱瘡1

35. 天疱瘡


臨床試験数 : 99 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002146-37-FR
(EUCTR)
24/01/201901/10/2018A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisA Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris Pemphigus vulgaris
MedDRA version: 20.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: INCB050465 0.3mg
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: INCB050465 1.0mg
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: INCB050465 2.5mg
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Incyte CorporationNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
18 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Canada;Italy